Trending Now - Promising New Treatments Offer Hope for Pancreatic Cancer Patients

WHO:

NBC News - The first person to receive a personalized mRNA vaccine for pancreatic cancer at Memorial Sloan Kettering has been cancer-free for six years.

Live Science - Dr. Devalingam Mahalingam, an oncologist at Northwestern University Feinberg School of Medicine, is a co-author of the study on elraglusib.

WHAT:

NBC News - An experimental mRNA vaccine for pancreatic cancer is showing major promise, with nearly all patients who responded to it still alive six years later.

Live Science - An experimental drug called elraglusib has doubled one-year survival rates for pancreatic cancer patients in a clinical trial.

Live Science - In a trial involving 286 patients with recently diagnosed pancreatic cancer, 50% of those receiving elraglusib and chemotherapy were alive after 10.1 months, compared to 7.2 months for those receiving chemotherapy alone.

Live Science - Of the patients given elraglusib, 42% lived a year after their diagnosis, compared to 22% of those who received only chemotherapy.

WHERE:

NBC News - The personalized mRNA vaccine was administered at Memorial Sloan Kettering.

Live Science - The study on elraglusib was conducted at Northwestern University Feinberg School of Medicine.

WHEN:

Live Science - The results of the trial showing elraglusib's safety and efficacy were published on April 14th, 2026.

Live Science - The trial involved patients who had been recently diagnosed with pancreatic cancer.

WHY:

Live Science - Pancreatic cancer has one of the poorest prognoses of all cancers, with only a 13% chance of surviving five years after diagnosis, often due to late detection.

Live Science - Elraglusib targets the protective web that pancreatic tumors build around themselves, helping immune molecules and chemotherapy penetrate the tumors.

HOW:

Live Science - Elraglusib suppresses a protein called glycogen synthase kinase-3 beta (GSK-3 beta), which helps pancreatic cancer cells resist programmed cell death.

Live Science - The drug was tested in a clinical trial where patients received chemotherapy with or without elraglusib.

(UPDATED April 19, 2026 01:20 UTC)

An experimental mRNA vaccine for pancreatic cancer, administered at Memorial Sloan Kettering, has shown remarkable results, with the first recipient remaining cancer-free for six years. In a recent clinical trial involving 286 patients, the drug elraglusib, when combined with chemotherapy, doubled one-year survival rates, with 42% of those treated surviving a year compared to just 22% for those receiving chemotherapy alone. The findings, published on Tuesday, highlight the potential of elraglusib to enhance treatment outcomes for a disease known for its poor prognosis, as it targets the protective barriers that pancreatic tumors create to resist treatment.